INOVIQ
LIVE

Serial Number

97427897

Owner

INOVIQ Limited

Attorney

Charles G. Zug

Filing Date

May 25, 2022

Add to watchlist:

No watchlists yet
View on USPTO

INOVIQ Trademark

Serial Number: 97427897 • Registration: 8300033

INOVIQ is a trademark filed by INOVIQ Limited on May 25, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

INOVIQ Limited (2 trademarks)

23 Normanby Road

Entity Type: 99

Trademark Details

Filing Date

May 25, 2022

Registration Date

June 16, 2026

Published for Opposition

October 15, 2024

Goods & Services

Biological reagents for scientific and research use for molecular targets for drug and vaccine development; reagents for medical research applications; reagents for medical research applications, namely, molecular targets for drug and vaccine development; biological reagents for use in molecular biology for research purposes; reagents for medical diagnosis research applications

Biotechnology medical apparatus for the prevention, diagnosis or treatment of cancer, neurodegenerative, inflammatory, and metabolic diseases; medical diagnostic apparatus and instruments for testing biofluids, plasma, serum, saliva, urine and cell cultures for sale in kit form; biotechnology medical apparatus, namely, medical apparatus for the capture of extracellular vesicles

Scientific research, clinical research, development, advisory and consultancy services in relation to antibody production; vaccine screening, in the nature of research and development of vaccines; advisory services relating to diagnostic products for scientific research, extracellular vesical (EV) isolations, creating custom NET builds, or developing diagnostic assays; providing diagnostic testing services for others for scientific research purposes; scientific research for medical purposes; scientific research for medical purposes, namely, research services relating to diagnostic products for scientific research, extracellular vesical (EV) isolations, creating custom NET builds, or developing diagnostic assays; diagnostic and research services and screening in the nature of research services in the field of diagnostic preparations; preparation of reports relating to medical, scientific and technical research; provision of information relating to medical, scientific and technical research; research and development of products; research and development of products, namely, new therapeutic products in the field of gene therapeutics and cell therapeutics; research and development of products, namely, extracellular vesicle-based diagnostic products, extracellular vesicle-based therapeutic products; laboratory research in the fields of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology; laboratory research services relating to research in the field of extracellular vesicle-based diagnostics and extracellular vesicle-based therapeutics; scientific laboratory research and analysis services; scientific laboratory research and analysis services for research and analysis of new products in the field of cell therapeutics; analysis of tissues for medical research; research and development services in the field of antibody generation; molecular target discovery and development services; recombinant human protein production cell line, namely, culturing of cells for others for scientific research purposes

Advisory services relating to medical diagnostic products; advisory services relating to medical diagnostic products, namely, medical diagnostic products for extracellular vesical (EV) isolations, creating custom NET builds, or developing diagnostic assays; Medical diagnostic testing services; medical diagnostic screening services in the field of diagnostic preparations

Pharmaceutical, biotechnology and medical preparations and substances for the prevention, diagnosis or treatment of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic diseases; pharmaceutical, biotechnology and medical preparations and substances for the treatment, reconstruction and repair of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic diseases using antibodies or exosomes; diagnostic preparations and reagents for medical purposes; diagnostic preparations for medical laboratory use and reagents for medical purposes, namely, extracellular vesicles, RNA, protein arrays or monoclonal antibodies; monoclonal antibodies for medical purposes; monoclonal antibody fragments for medical purposes; monoclonal antibody conjugates for medical purposes; preparations for the treatment, reconstruction and repair of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic diseases using antibodies or exosomes; immunological antibodies for medical use; biological preparations for the treatment of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic diseases for medical purposes; biological preparations for the treatment of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic diseases for pharmaceutical purposes; biological substances for the treatment of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic diseases for medical use; monoclonal antibodies for diagnostic medical use; monoclonal antibodies for medical use; monoclonal antibodies for therapeutic purposes; products containing monoclonal antibodies for use in medicine; proteins for medical use in binding antibodies; proteins for medical use in detecting antibodies; reagents for use in the development of monoclonal antibodies for medical purposes; tagged antibodies for medical use; vaccines; vaccines against cancer, viral or bacterial infection; vaccines for human use; vaccine adjuvants; diagnostic preparations, reagents, pharmaceutical and biochemical anti-cancer substances, products for the prevention, diagnosis or treatment of cancer, neurodegenerative, inflammatory, and metabolic diseases, and testing materials, namely, diagnostic test strips, immunoassays, PCR or genetic tests for in-vitro diagnostic use for medical purposes; diagnostic preparations and reagents for medical purposes, namely, diagnostic biomarker reagents for medical purposes; reagents for use in diagnostic tests for medical purposes; protein arrays for use in recombinant DNA technology for medical diagnosis purposes; biological reagents for use in molecular biology for medical purposes; diagnostic preparations and reagents for medical purposes, namely, diagnostic reagents for in-vitro use for medical purposes, reagents for in-vitro laboratory use for medical purposes, reagents for use in diagnostic tests for medical purposes, diagnostic reagents for medical use for sale in kit form; reagents in kit form for conducting enzyme-linked immunosorbent assays (ELISA) for medical purposes; pharmaceutical, biotechnology and medical preparations and substances for medical use, namely, immunotherapeutic agents for the treatment of cancer; nucleic acid substances for use in genetic probe assay kits for medical use; preparations for the treatment, reconstruction and repair of antibodies, namely, biological preparations for pharmaceutical purposes

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jun 16, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Jun 16, 2026 R.PR
1(B) BASIS DELETED; PROCEED TO REGISTRATION
May 28, 2026 DP1B
CASE ASSIGNED TO INTENT TO USE PARALEGAL
May 27, 2026 AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Nov 6, 2025 AITU
NOTICE OF ALLOWANCE CANCELLED
May 27, 2025 IUCN
TEAS DELETE 1(B) BASIS RECEIVED
May 27, 2025 D1BR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 26, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 15, 2024 NPUB
PUBLISHED FOR OPPOSITION
Oct 15, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 25, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 12, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Sep 12, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 12, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Sep 12, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 12, 2024 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 9, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 9, 2024 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Sep 9, 2024 ERFR
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jun 11, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jun 11, 2024 XELR
NOTIFICATION OF FINAL REFUSAL EMAILED
Mar 12, 2024 GNFN
FINAL REFUSAL E-MAILED
Mar 12, 2024 GNFR
FINAL REFUSAL WRITTEN
Mar 12, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 12, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 12, 2024 CRFA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 12, 2024 CHAN
ASSIGNED TO LIE
Feb 12, 2024 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 21, 2023 TROA
TEAS VOLUNTARY AMENDMENT RECEIVED
Sep 21, 2023 PARI
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jun 20, 2023 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jun 20, 2023 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 21, 2023 GNRN
NON-FINAL ACTION E-MAILED
Mar 21, 2023 GNRT
NON-FINAL ACTION WRITTEN
Mar 21, 2023 CNRT
ASSIGNED TO EXAMINER
Mar 10, 2023 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Jun 2, 2022 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 1, 2022 NWOS
NEW APPLICATION ENTERED
May 28, 2022 NWAP